{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"A DLT is defined as an Adverse Event that is likely related to the study medication or combination, and fulfills any one of the following criteria, graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0:\n\n1. Any death not clearly due to the underlying disease or extraneous causes\n2. Neutropenic fever 2. Any Grade ≥3 non-hematologic toxicity\n3. Grade ≥4 neutropenia or thrombocytopenia \\>7 days\n4. Grade ≥3 thrombocytopenia with bleeding\n5. Grade ≥3 nausea/vomiting or diarrhea\\>72 hours with adequate antiemetic and other supportive care\n6. Grade ≥3 fatigue ≥1 week\n7. Grade ≥3 electrolyte abnormality that lasts\\>72 hours, unless the Participant has clinical symptoms, in which case all Grade 3+electrolyte abnormality regardless of duration should count as a DLT\n8. Grade ≥3 prolongation of QT interval corrected using the Fridericia formula on 2 separate electrocardiogram readings approximately 5 min apart.","groups":[{"description":"Participants received 10 mg dose of LY3435151 via intravenous (IV) as an IV push or IV bolus infusion.","id":"OG000","title":"10 mg LY3435151"}],"populationDescription":"Zero participants were analyzed. This outcome was not determined because the study terminated before completion of Part A of the dose escalation period.","reportingStatus":"POSTED","timeFrame":"Baseline through Cycle 2 (21 Day Cycles)","title":"Number of Participants With LY3435151 Dose-Limiting Toxicities (DLTs)","type":"PRIMARY"}